当前位置： SCI文献检索 > BMC CANCER期刊下所有文献 > EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.

Abstract：

BACKGROUND:Epidermal growth factor receptor exon 20 insertion (EGFRex20ins) mutations represent approximately 4-12% of EGFR mutations and are generally refractory to the 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs). Development of effective therapies for patients with EGFRex20ins mutant non-small-cell lung carcinoma (NSCLC) represents a great unmet need. Preclinical models have shown that osimertinib is active in NSCLC harboring EGFRex20ins, while the antitumor activity of osimertinib remains to be evaluated in patients with EGFRex20ins mutations. METHODS:Tumor genotyping was performed in 2316 Chinese NSCLC cases with targeted next generation sequencing (NGS) covering the whole exons of EGFR gene. The frequency and genetic characteristics of EGFRexon20ins mutations were analyzed. Furthermore, six patients with specific EGFRexon20ins mutations and receiving osimertinib 80 mg once daily were retrospectively included to assess the antitumor activity and safety of monotherapy osimertinib. RESULTS:EGFRex20ins mutations were identified in 4.8% (53/1095) of EGFR mutant NSCLC and 2.3% (53/2316) of all NSCLC cases. The most frequently identified EGFRexon20ins is A767_V769dup (17/53,32.1%). We found that the genetic characteristics of EGFRex20ins mutations in Chinese patients with NSCLC were comparable to those reported in Caucasian patients. Four patients with osimertinib therapy achieved partial response and the rest stable disease. Median progression free survival (PFS) was 6.2 months (95% confidence interval 5.0-12.9 months; range 4.9-14.6 months). The most common adverse events (AEs) were diarrhea (2/6), pruritis (2/6), stomatitis (1/6) and nausea (1/6). No grade 3 or more AEs were documented. CONCLUSIONS:This study revealed that the genetic characteristics of EGFRex20ins mutations in Chinese patients with NSCLC were comparable to those reported in Caucasian patients. Furthermore, our study firstly demonstrated promising antitumor activity of osimertinib in certain EGFRex20ins mutant advanced NSCLC patients, indicating that osimertinib treatment for EGFRex20ins positive patients deserves further study.

journal_name

BMC Cancer

journal_title

BMC cancer

authors

Fang W,Huang Y,Hong S,Zhang Z,Wang M,Gan J,Wang W,Guo H,Wang K,Zhang L

doi

10.1186/s12885-019-5820-0

subject

Has Abstract

pub_date

2019-06-17 00:00:00

pages

595

issue

issn

1471-2407

pii

10.1186/s12885-019-5820-0

journal_volume

pub_type

杂志文章

在线工具

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.